Arca
Skip to content
Tools
Tools

Label Changes: Rowasa (mesalamine)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Rowasa label DailyMed has published, from Viatris Specialty LLC, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 18
  • Sections changed, version 17 to 18: 5

What changed from version 17 to version 18

May 15, 2026 to Aug 7, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Warnings and precautionsChanged · 71 words added
  2. Adverse reactionsChanged · 12 words added
  3. Use in specific populationsChanged · 1 word added, 1 removed
  4. How suppliedChanged · 1 word added, 1 removed
  5. Patient counseling informationChanged · 33 words added, 3 removed

Warnings and precautions

Changed71 words added
22 unchanged lines
Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection because of the similarity in the chromatograms of normetanephrine and the main metabolite of mesalamine, N‑acetyl‑5‑aminosalicylic acid (N‑Ac‑5‑ASA). Consider an alternative, selective assay for normetanephrine.
5.9 Intracranial Hypertension
Intracranial hypertension has been reported postmarketing in patients receiving mesalamine and sulfasalazine. Signs and symptoms of intracranial hypertension can include severe or recurrent headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy. These signs and symptoms are similar to idiopathic intracranial hypertension. If an unusual headache or visual disturbance occurs during treatment, immediately discontinue ROWASA and refer the patient for further evaluation.

Adverse reactions

Changed12 words added
8 unchanged lines
•Nephrolithiasis [see Warnings and Precautions (5.7)]
•Intracranial Hypertension [see Warnings and Precautions (5.9)]
6.1 Clinical Trials Experience
15 unchanged lines
Hepatic Disorders: elevated liver enzymes, hepatic failure [see Warnings and Precautions (5.4)]
Immune System Disorders: vasculitis
Nervous System: intracranial hypertension
Renal and Urinary Disorders: acute renal failure, chronic renal failure, interstitial nephritis, nephrogenic diabetes insipidus, nephrolithiasis, nephrotoxicity [see Warnings and Precautions (5.2), (5.7) ]
• Urine discoloration occurring ex-vivo caused by contact of mesalamine including inactive metabolite, with surfaces or water treated with hypochlorite-containing bleach
3 unchanged lines

Use in specific populations

Changed1 word added, 1 removed
9 unchanged lines
Human Data
Published data from meta-analyses, cohort studies and case series on the use of mesalamine, the active moiety of ROWASA, during early pregnancy (first trimester) and throughout pregnancy have not reliably informed an association of mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes. There is no clear evidence that mesalamine exposure in early pregnancy is associated with an increaseincreased risk in major congenital malformations, including cardiac malformations. Published epidemiologic studies have important methodological limitations which hinder interpretation of the data, including inability to control for confounders, such as underlying maternal disease, and maternal use of concomitant medications, and missing information on the dose and duration of use for mesalamine products.
Animal Data
15 unchanged lines

How supplied

Changed1 word added, 1 removed
7 unchanged lines
Storage
Store at controlled room temperature 20°C to 25°C (68°CF to 77°F); Excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Once the foil wrapped unit of seven bottles is opened, all enemas should be used promptly as directed by your physician. Contents of enemas removed from the foil pouch may darken with time. Slight darkening will not affect potency, however, enemas with dark brown contents should be discarded.

Patient counseling information

Changed33 words added, 3 removed
12 unchanged lines
Nephrolithiasis
Instruct patients to drink an adequate amount of fluids during treatment in order to minimize the risk of kidney stone formation and to contact their healthcare provider if they experience signs or symptoms of a kidney stone (e.g., severe side or back pain, blood in the urine) [see Warnings and Precautions (5.87) ].
Blood Disorders
Inform elderly patients and those taking azathioprine or 6-mercaptopurine of the risk for blood disorders and the need for periodic monitoring of complete blood cell counts and platelet counts while on therapy. Advise patients to complete all blood tests ordered by their healthcare provider [see Drug Interactions (7.2), Use in Specific Populations (8.5)].
Intracranial Hypertension
Instruct patients to discontinue ROWASA and immediately report to their healthcare provider if unusual headache or visual disturbances occur [see Warnings and Precautions (5.9)].
Administration
9 unchanged lines
•Advise patients that urine may become discolored reddish-brown while taking ROWASA when it comes in contact with surfaces or water treated with hypochlorite-containing bleach. If discolored urine is observed, advise patients to observe their urine flow. Report to the healthcare provider only if urine is discolored on leaving the body, before contact with any surface or water (e.g., in the toilet).
IN-003606-08X11
Rev. x/202x
Distributed by: MEDA PHARMACEUTICALS Canonsburg, PA 15317 U.S.A.
© 20242026 Viatris Inc.
ROWASA is a registered trademark of Alaven Pharmaceutical LLC, a Viatris Company.
1 unchanged line

Unchanged: Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Drug interactions, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, Patient information, PRINCIPAL DISPLAY PANEL – 4.0g/60mL.

Every version

18 versions of set e505ab99-1943-4216-a178-4d5dbe64e3b2, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.